Nurix Therapeutics To Participate in Upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit
Nurix Therapeutics (Nasdaq: NRIX), a clinical-stage biopharmaceutical company, has announced its participation in the upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit in Boston from September 9-10, 2024. Dr. Gwenn M. Hansen, the company's chief scientific officer, will present an update on Nurix's Degrader-Antibody Conjugate (DAC) platform on Tuesday, September 10, from 9:05 to 9:25 a.m. ET.
The presentation, titled 'Targeted Protein Degraders As Next Generation Antibody Payloads', will showcase Nurix's innovative approach to developing targeted protein modulation drugs for cancer and inflammatory diseases. Interested parties can access the presentation slides from September 9, 2024, through the Investors section of the Nurix website under Events and Presentations.
Nurix Therapeutics (Nasdaq: NRIX), una società biofarmaceutica in fase clinica, ha annunciato la sua partecipazione al prossimo ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit che si terrà a Boston dal 9 al 10 settembre 2024. Il Dr. Gwenn M. Hansen, direttore scientifico dell'azienda, presenterà un aggiornamento sulla piattaforma Degrader-Antibody Conjugate (DAC) di Nurix martedì 10 settembre, dalle 9:05 alle 9:25 a.m. ET.
La presentazione, intitolata 'Targeted Protein Degraders As Next Generation Antibody Payloads', metterà in luce l'approccio innovativo di Nurix nello sviluppo di farmaci per la modulazione mirata delle proteine per il trattamento del cancro e delle malattie infiammatorie. Le parti interessate potranno accedere alle diapositive della presentazione dal 9 settembre 2024, nella sezione Investitori del sito web di Nurix, sotto Eventi e Presentazioni.
Nurix Therapeutics (Nasdaq: NRIX), una compañía biofarmacéutica en etapa clínica, ha anunciado su participación en la próxima ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit en Boston del 9 al 10 de septiembre de 2024. La Dra. Gwenn M. Hansen, directora científica de la compañía, presentará una actualización sobre la plataforma Degrader-Antibody Conjugate (DAC) de Nurix el martes 10 de septiembre, de 9:05 a 9:25 a.m. ET.
La presentación, titulada 'Targeted Protein Degraders As Next Generation Antibody Payloads', destacará el enfoque innovador de Nurix para desarrollar fármacos de modulación de proteínas dirigidos para el tratamiento del cáncer y enfermedades inflamatorias. Las partes interesadas podrán acceder a las diapositivas de la presentación desde el 9 de septiembre de 2024, en la sección de Inversores del sitio web de Nurix bajo
Nurix Therapeutics (Nasdaq: NRIX)는 클리니컬 단계의 생명공학 회사로, 오는 ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit에 참여한다고 발표했습니다. 이 행사는 2024년 9월 9일부터 10일까지 보스턴에서 열립니다. 회사의 수석 과학자 Dr. Gwenn M. Hansen은 9월 10일 화요일 오전 9시 5분부터 9시 25분까지 Degrader-Antibody Conjugate (DAC) 플랫폼에 대한 업데이트를 발표할 예정입니다.
프레젠테이션 제목은 'Targeted Protein Degraders As Next Generation Antibody Payloads'로, Nurix의 혁신적인 접근 방식을 통해 암 및 염증성 질환을 위한 표적 단백질 조절 약물 개발을 선보일 것입니다. 관심 있는 분들은 2024년 9월 9일부터 Nurix 웹사이트의 투자자 섹션에서 이벤트 및 프레젠테이션 아래에서 발표 자료를 확인하실 수 있습니다.
Nurix Therapeutics (Nasdaq: NRIX), une société biopharmaceutique en phase clinique, a annoncé sa participation au prochain ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit à Boston du 9 au 10 septembre 2024. Dr Gwenn M. Hansen, le directeur scientifique de la société, présentera une mise à jour sur la plateforme Degrader-Antibody Conjugate (DAC) de Nurix le mardi 10 septembre, de 9h05 à 9h25 ET.
La présentation, intitulée 'Targeted Protein Degraders As Next Generation Antibody Payloads', mettra en lumière l'approche innovante de Nurix dans le développement de médicaments modulant les protéines ciblées pour le cancer et les maladies inflammatoires. Les parties intéressées pourront accéder aux diapositives de la présentation à partir du 9 septembre 2024, dans la section Investisseurs du site web de Nurix sous Événements et Présentations.
Nurix Therapeutics (Nasdaq: NRIX), ein biopharmazeutisches Unternehmen in klinischer Phase, hat seine Teilnahme am kommenden ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit in Boston vom 9. bis 10. September 2024 angekündigt. Dr. Gwenn M. Hansen, der wissenschaftliche Direktor des Unternehmens, wird am Dienstag, dem 10. September, von 9:05 bis 9:25 Uhr ET ein Update zur Plattform Degrader-Antibody Conjugate (DAC) von Nurix präsentieren.
Die Präsentation mit dem Titel 'Targeted Protein Degraders As Next Generation Antibody Payloads' wird Nurix' innovativen Ansatz zur Entwicklung gezielter Proteinmodulationsmedikamente gegen Krebs und entzündliche Erkrankungen präsentieren. Interessierte können die Präsentationsfolien ab dem 9. September 2024 im Bereich Investoren der Nurix-Website unter Veranstaltungen und Präsentationen einsehen.
- None.
- None.
SAN FRANCISCO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix, will present an update on Nurix’s Degrader-Antibody Conjugate (DAC) platform at the ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit being held in Boston from September 9-10, 2024.
Title: Targeted Protein Degraders As Next Generation Antibody Payloads
Conference: ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit
Date and time: Tuesday, September 10, 9:05 – 9:25 a.m. ET
The slides for this presentation may be accessed beginning on September 9, 2024, via a link in the Investors section of the Nurix website under Events and Presentations.
About Nurix
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform, to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types including T cell and NK cells. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.
Contacts:
Investors
Jason Kantor, Ph.D.
Nurix Therapeutics
ir@nurixtx.com
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com
Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
FAQ
When and where is Nurix Therapeutics presenting at the ADC & Radiopharmaceuticals Summit?
What is the topic of Nurix Therapeutics' presentation at the 2024 ADC Summit?
Who will be presenting for Nurix Therapeutics at the September 2024 ADC Summit?
How can investors access Nurix Therapeutics' presentation slides from the 2024 ADC Summit?
What is the main focus of Nurix Therapeutics' drug development?
